Zobrazeno 1 - 10
of 211
pro vyhledávání: '"Si Yang Liu"'
Autor:
Richard A. Hickman, Alexandra M. Miller, Bridget M. Holle, Justin Jee, Si-Yang Liu, Dara Ross, Helena Yu, Gregory J. Riely, Christina Ombres, Alexandra N. Gewirtz, Anne S. Reiner, Subhiksha Nandakumar, Adam Price, Thomas J. Kaley, Maya S. Graham, Chad Vanderbilt, Satshil Rana, Katherine Hill, Kiana Chabot, Carl Campos, Khedoudja Nafa, Neerav Shukla, Matthias Karajannis, Bob Li, Michael Berger, Marc Ladanyi, Elena Pentsova, Adrienne Boire, A. Rose Brannon, Tejus Bale, Ingo K. Mellinghoff, Maria E. Arcila
Publikováno v:
Acta Neuropathologica Communications, Vol 12, Iss 1, Pp 1-13 (2024)
Abstract The characterization of genetic alterations in tumor samples has become standard practice for many human cancers to achieve more precise disease classification and guide the selection of targeted therapies. Cerebrospinal fluid (CSF) can serv
Externí odkaz:
https://doaj.org/article/d891582bd5b340c8aff11cbf672c3107
Publikováno v:
Renal Failure, Vol 46, Iss 2 (2024)
Externí odkaz:
https://doaj.org/article/f623476bc6914f2daa8e87f1bd5118ab
Publikováno v:
Human Vaccines & Immunotherapeutics, Vol 20, Iss 1 (2024)
Externí odkaz:
https://doaj.org/article/806d9d21266e42f5af6ddd2183a22b78
Publikováno v:
Human Vaccines & Immunotherapeutics, Vol 20, Iss 1 (2024)
Externí odkaz:
https://doaj.org/article/c4f9d2639a1e4ef4965c6e20b5f98e90
Autor:
Song Dong, PhD, Bingfa Yan, PhD, Si-Yang Liu, PhD, Xuan Gao, PhD, Hui-Zhao Hong, MD, Hong-Ji Li, MD, Wei Gao, PhD, Hong-Hong Yan, PhD, Si-Yang Maggie Liu, PhD, Hai-Yan Tu, PhD, Yi Pan, PhD, Qing Zhou, PhD, Xue-Ning Yang, PhD, Xue-Feng Xia, PhD, Xin Yi, PhD, Wen-Zhao Zhong, PhD, Yi-Long Wu, MD, Jia-Tao Zhang, PhD
Publikováno v:
JTO Clinical and Research Reports, Vol 6, Iss 1, Pp 100758- (2025)
Introduction: EGFR tyrosine kinase inhibitor (TKI) is the standard adjuvant treatment for patients with stages IB to IIIA EGFR-mutated NSCLC. Nevertheless, adapting this approach to include a molecular residual disease (MRD)-guided de-escalation stra
Externí odkaz:
https://doaj.org/article/53643bd155c048d5bc49ea739a649af6
Autor:
Si-Yang Liu, Song Dong, Xue-Ning Yang, Ri-Qiang Liao, Ben-Yuan Jiang, Qun Wang, Xiao-Song Ben, Gui-Bin Qiao, Jun-Tao Lin, Hong-Hong Yan, Li-Xu Yan, Qiang Nie, Hai-Yan Tu, Bin-Chao Wang, Jin-Ji Yang, Qing Zhou, Hong-Rui Li, Ke Liu, Wendy Wu, Si-Yang Maggie Liu, Wen-Zhao Zhong, Yi-Long Wu
Publikováno v:
Signal Transduction and Targeted Therapy, Vol 8, Iss 1, Pp 1-10 (2023)
Abstract This prospective multicenter phase II study evaluated the clinical efficacy of neoadjuvant nivolumab-exclusive (N) and nivolumab–chemotherapy (N/C) combinations based on PD-L1 expression. Eligible patients exhibited resectable clinical sta
Externí odkaz:
https://doaj.org/article/fac0f07d3dc04d809e388bf7352818af
Publikováno v:
Journal of Hematology & Oncology, Vol 16, Iss 1, Pp 1-20 (2023)
Abstract Research on biomarker-driven therapy and immune check-point blockade in non-small cell lung cancer (NSCLC) is rapidly evolving. The width and depth of clinical trials have also dramatically improved in an unprecedented speed. The personalize
Externí odkaz:
https://doaj.org/article/ea64f79867e24340851b91a0764ca52b
Autor:
Mikhail Linetsky, Anshula Mondal, Si-Yang Liu, Abby M. Hite, Shravani Enduri, Yu-Shiuan Cheng, Beatriz Feijo, Graham Kang, Nana Arhin, Hong Zeng, Olivia R. Laniak, John Denker, Robert G. Salomon
Publikováno v:
Results in Chemistry, Vol 6, Iss , Pp 100995- (2023)
γ-Hydroxyalkenals, 4-hydroxynonenal (HNE) and phospholipid esters of 4-hydroxy-8-oxooctenoic acid (HOOA-PL), are produced from the alkyl and carboxyl termini of arachidonyl phospholipids by radical-induced oxidative cleavage. Metabolism of HNE by Mi
Externí odkaz:
https://doaj.org/article/61caed6a19c04a548a9e996cee70bce8
Autor:
Si-Yang Maggie Liu, Cunte Chen, Yi-Kai Zhang, Wen-Zhao Zhong, Yi-Long Wu, Si-Yang Liu, Yangqiu Li
Publikováno v:
Biomarker Research, Vol 11, Iss 1, Pp 1-5 (2023)
Abstract Background ADJUVANT-CTONG1104 reported a favorable survival outcome from adjuvant gefitinib treatment over chemotherapy in EGFR-mutant non-small cell lung cancer (NSCLC) patients. However, heterogeneous benefit from EGFR-TKIs and chemotherap
Externí odkaz:
https://doaj.org/article/04f97971b0dd460283cc54bc37b254f6
Autor:
Wen-Zhao Zhong, Hong-Hong Yan, Ke-Neng Chen, Chun Chen, Chun-Dong Gu, Jun Wang, Xue-Ning Yang, Wei-Min Mao, Qun Wang, Gui-Bin Qiao, Ying Cheng, Lin Xu, Chang-Li Wang, Ming-Wei Chen, Xiao-Zheng Kang, Wan-Pu Yan, Ri-Qiang Liao, Jin-Ji Yang, Xu-Chao Zhang, Si-Yang Liu, Qing Zhou, Yi-Long Wu
Publikováno v:
Signal Transduction and Targeted Therapy, Vol 8, Iss 1, Pp 1-8 (2023)
Abstract EMERGING-CTONG 1103 showed improved progression-free survival (PFS) with neoadjuvant erlotinib vs. chemotherapy for patients harbouring EGFR sensibility mutations and R0 resected stage IIIA-N2 non-small cell lung cancer (NSCLC) (NCT01407822)
Externí odkaz:
https://doaj.org/article/1f184cb431924c6cb798d962d9892a83